Skip to menu Skip to content Skip to footer
Associate Professor Simone M Goldinger
Associate Professor

Simone M Goldinger

Email: 

Overview

Background

A/ Professor Simone M Goldinger is a clinician-researcher in dermatology with a subspecialty focus on skin cancer and digital health. Her work sits at the intersection of clinical dermatology, artificial intelligence, and longitudinal imaging, with a particular emphasis on non-melanoma skin cancer detection and surveillance. Her current research develops and validates equitable, data-driven approaches to skin cancer diagnosis, drawing on large-scale longitudinal datasets to improve accuracy, address algorithmic bias, and support real-world clinical implementation. A central goal is ensuring these AI-powered tools are effective across diverse patient populations and translatable into everyday clinical practice.

Earlier in her career, A/Prof Goldinger specialised in dermato-oncology, focusing on metastatic melanoma and the cutaneous toxicities associated with immune checkpoint inhibitors and targeted therapies. This background in advanced disease management provides a strong translational foundation for her current work, connecting insights from late-stage oncology to earlier detection, risk stratification, and long-term monitoring. Her research bridges clinical medicine, data science, and health equity — with the aim of improving outcomes for patients with skin cancer in Australia and beyond.

Availability

Associate Professor Simone M Goldinger is:
Available for supervision

Qualifications

  • Bachelor (Honours) of Medicine, University of Zurich
  • Masters (Research) of Medicine and Surgery and Medical Science, University of Zurich
  • Doctoral (Research), University of Zurich
  • Professional Doctorate, University of Zurich
  • Fellow, Australasian College of Dermatologists, Australasian College of Dermatologists

Research impacts

Skin cancer is the most common cancer in Australia, and early detection can save lives. A/Prof Goldinger's research is working to make skin cancer diagnosis smarter, faster, and fairer — developing AI tools that can assist clinicians in spotting cancers earlier and monitoring high-risk patients more effectively over time. A key focus is equity: ensuring that AI diagnostic systems work well for all patients, regardless of skin tone or background. By identifying and correcting for bias in these tools before they reach the clinic, this research helps reduce the risk that AI makes existing health disparities worse. Her earlier work on the skin side effects of cancer treatments — including immunotherapy and targeted therapies — has contributed to better recognition and management of these complications, helping patients stay on life-saving treatments for longer. Together, this research aims to improve outcomes for skin cancer patients across Australia, support clinicians with better decision-making tools, and ensure that advances in digital health benefit everyone equitably.

Works

Search Professor Simone M Goldinger’s works on UQ eSpace

137 works between 2006 and 2026

1 - 20 of 137 works

2026

Journal Article

Evolving landscape of consumer‐based smartphone apps for skin cancer prevention and early detection

Hussain, Nurul Amanina Binte, King, Abigail, Horsham, Caitlin, Goldinger, Simone M. and Janda, Monika (2026). Evolving landscape of consumer‐based smartphone apps for skin cancer prevention and early detection. Journal of the European Academy of Dermatology and Venereology jdv.70464. doi: 10.1111/jdv.70464

Evolving landscape of consumer‐based smartphone apps for skin cancer prevention and early detection

2025

Journal Article

The impact of multidisciplinary research on progress in skin cancer prevention

Susanto, Alyssa, Primiero, Clare, Goldinger, Simone M., Soyer, H. Peter and Janda, Monika (2025). The impact of multidisciplinary research on progress in skin cancer prevention. Cancers, 17 (21) 3473, 1-21. doi: 10.3390/cancers17213473

The impact of multidisciplinary research on progress in skin cancer prevention

2025

Journal Article

Three-dimensional total body photography enables automated obesity-related comorbidity screening in dermatology

Susanto, Alyssa, Kahler, Sam, Dulanjala Sewwandi, M. A. Nayomi, Mothershaw, Adam, Goldinger, Simone M., Mar, Victoria, Janda, Monika, Soyer, H.Peter and Primiero, Clare (2025). Three-dimensional total body photography enables automated obesity-related comorbidity screening in dermatology. Journal of Investigative Dermatology, 146 (3), 855-858. doi: 10.1016/j.jid.2025.09.001

Three-dimensional total body photography enables automated obesity-related comorbidity screening in dermatology

2025

Journal Article

Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab

von Bubnoff, Dagmar, Schmitt, Christina, Goldinger, Simone M., Schadendorf, Dirk, Kaehler, Katharina C., Hafner, Christian, Kramer, Nora, Froehlich, Waltraud, Dummer, Reinhard, Berking, Carola, Schliep, Stefan, Kirchberger, Michael C. and Heinzerling, Lucie (2025). Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab. PLoS One, 20 (5) e0321937, 1-15. doi: 10.1371/journal.pone.0321937

Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab

2025

Journal Article

An updated review of immune checkpoint inhibitors in cutaneous oncology: beyond melanoma

Pham, James P., Staeger, Ramon, Joshua, Anthony M., Liu, Jia, da Silva, Ines P., Dummer, Reinhard and Goldinger, Simone M. (2025). An updated review of immune checkpoint inhibitors in cutaneous oncology: beyond melanoma. European Journal of Cancer, 214 115121, 1-11. doi: 10.1016/j.ejca.2024.115121

An updated review of immune checkpoint inhibitors in cutaneous oncology: beyond melanoma

2025

Journal Article

Efficacy of immune checkpoint inhibitors in advanced mucosal melanoma: a systematic review and meta-analysis

Pham, James P., Kondo, Mickey, Hurwitz, Joshua, Cosman, Rasha, Goldinger, Simone M., Dummer, Reinhard, Sim, Hao-Wen and Joshua, Anthony M. (2025). Efficacy of immune checkpoint inhibitors in advanced mucosal melanoma: a systematic review and meta-analysis. EJC Skin Cancer, 3 100756. doi: 10.1016/j.ejcskn.2025.100756

Efficacy of immune checkpoint inhibitors in advanced mucosal melanoma: a systematic review and meta-analysis

2024

Journal Article

Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: a systematic review and meta‐analysis

Pham, James P., Rodrigues, Anthony, Goldinger, Simone M., Sim, Hao‐Wen and Liu, Jia (2024). Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: a systematic review and meta‐analysis. Experimental Dermatology, 33 (1) e14978, 1-7. doi: 10.1111/exd.14978

Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: a systematic review and meta‐analysis

2023

Conference Publication

Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and metaanalysis

Pham, J. P., Hurwitz, J., Cosman, R., Goldinger, S. M., Sim, H. W., Dummer, R. and Joshua, A. M. (2023). Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and metaanalysis. Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.09.2261

Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and metaanalysis

2023

Journal Article

Chemotherapy in cutaneous melanoma: is there still a role?

Pham, James P., Joshua, Anthony M., da Silva, Ines P., Dummer, Reinhard and Goldinger, Simone M. (2023). Chemotherapy in cutaneous melanoma: is there still a role?. Current Oncology Reports, 25 (6), 609-621. doi: 10.1007/s11912-023-01385-6

Chemotherapy in cutaneous melanoma: is there still a role?

2022

Journal Article

Merkel cell carcinoma in situ: a systematic review of prognosis and management

Truong, Kelvin, Goldinger, Simone M., Chou, Shaun, Howle, Julie R., Veness, Michael J., Fernandez‐Peñas, Pablo and Varey, Alexander H. R. (2022). Merkel cell carcinoma in situ: a systematic review of prognosis and management. Australasian Journal of Dermatology, 63 (1), e6-e12. doi: 10.1111/ajd.13758

Merkel cell carcinoma in situ: a systematic review of prognosis and management

2022

Journal Article

Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis

Goldinger, Simone M., Buder-Bakhaya, Kristina, Lo, Serigne N., Forschner, Andrea, McKean, Meredith, Zimmer, Lisa, Khoo, Chloe, Dummer, Reinhard, Eroglu, Zeynep, Buchbinder, Elizabeth I., Ascierto, Paolo A., Gutzmer, Ralf, Rozeman, Elisa A., Hoeller, Christoph, Johnson, Douglas B., Gesierich, Anja, Kölblinger, Peter, Bennannoune, Naima, Cohen, Justine V., Kähler, Katharina C., Wilson, Melissa A., Cebon, Jonathan, Atkinson, Victoria, Smith, Jessica L., Michielin, Olivier, Long, Georgina V., Hassel, Jessica C., Weide, Benjamin, Haydu, Lauren E. ... Menzies, Alexander M. (2022). Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 162, 22-33. doi: 10.1016/j.ejca.2021.11.022

Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis

2021

Journal Article

Toxic epidermal necrolysis-like lupus erythematosus: a condition to exclude in all patients with possible Stevens-Johnson syndrome/toxic epidermal necrolysis

Truong, K., Goldinger, S., Kim, J., Smith, A. and Fernandez-Penas, P. (2021). Toxic epidermal necrolysis-like lupus erythematosus: a condition to exclude in all patients with possible Stevens-Johnson syndrome/toxic epidermal necrolysis. Journal of the European Academy of Dermatology and Venereology, 36 (3), E218-E221. doi: 10.1111/jdv.17753

Toxic epidermal necrolysis-like lupus erythematosus: a condition to exclude in all patients with possible Stevens-Johnson syndrome/toxic epidermal necrolysis

2021

Journal Article

Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition

Knispel, Sarah, Gassenmaier, Maximilian, Menzies, Alexander M., Loquai, Carmen, Johnson, Douglas B., Franklin, Cindy, Gutzmer, Ralf, Hassel, Jessica C., Weishaupt, Carsten, Eigentler, Thomas, Schilling, Bastian, Schummer, Patrick, Sirokay, Judith, Kiecker, Felix, Owen, Carina N., Fleischer, Maria, Cann, Christopher, Kaehler, Katharina C., Mohr, Peter, Bluhm, Leonie, Niebel, Dennis, Thoms, Kai-Martin, Goldinger, Simone M., Reinhardt, Lydia, Meier, Friedegund, Berking, Carola, Reinhard, Raphael, Susok, Laura, Ascierto, Paolo A. ... Zimmer, Lisa (2021). Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. European Journal of Cancer, 148, 61-75. doi: 10.1016/j.ejca.2021.01.034

Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition

2020

Journal Article

Long-term response to intermittent binimetinib in patients with NRAS-mutant melanoma

Matter, Alexandra Valeska, Micaletto, Sara, Urner-Bloch, Ursula, Dummer, Reinhard and Goldinger, Simone M. (2020). Long-term response to intermittent binimetinib in patients with NRAS-mutant melanoma. Oncologist, 25 (11), E1593-E1597. doi: 10.1634/theoncologist.2019-0656

Long-term response to intermittent binimetinib in patients with NRAS-mutant melanoma

2020

Journal Article

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (vol 25, pg 1915, 2019)

Liu, David, Schilling, Bastian, Liu, Derek, Sucker, Antje, Livingstone, Elisabeth, Jerby-Arnon, Livnat, Zimmer, Lisa, Gutzmer, Ralf, Satzger, Imke, Loquai, Carmen, Grabbe, Stephan, Vokes, Natalie, Margolis, Claire A., Conway, Jake, He, Meng Xiao, Elmarakeby, Haitham, Dietlein, Felix, Miao, Diana, Tracy, Adam, Gogas, Helen, Goldinger, Simone M., Utikal, Jochen, Blank, Christian U., Rauschenberg, Ricarda, von Bubnoff, Dagmar, Krackhardt, Angela, Weide, Benjamin, Haferkamp, Sebastian, Kiecker, Felix ... Schadendorf, Dirk (2020). Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (vol 25, pg 1915, 2019). Nature Medicine, 26 (7), 1147-1147. doi: 10.1038/s41591-020-0975-4

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (vol 25, pg 1915, 2019)

2019

Journal Article

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

Liu, David, Schilling, Bastian, Liu, Derek, Sucker, Antje, Livingstone, Elisabeth, Jerby-Amon, Livnat, Zimmer, Lisa, Gutzmer, Ralf, Satzger, Imke, Loquai, Carmen, Grabbe, Stephan, Vokes, Natalie, Margolis, Claire A., Conway, Jake, He, Meng Xiao, Elmarakeby, Haitham, Dietlein, Felix, Miao, Diana, Tracy, Adam, Gogas, Helen, Goldinger, Simone M., Utikal, Jochen, Blank, Christian U., Rauschenberg, Ricarda, von Bubnoff, Dagmar, Krackhardt, Angela, Weide, Benjamin, Haferkamp, Sebastian, Kiecker, Felix ... Schadendorf, Dirk (2019). Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nature Medicine, 25 (12), 1916-1927. doi: 10.1038/s41591-019-0654-5

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

2019

Journal Article

Binimetinib in heavily pretreated patients with NRAS‐mutant melanoma with brain metastases

Goldinger, S. M., Valeska Matter, A., Urner‐Bloch, U., Narainsing, J., Micaletto, S., Blume, I., Mangana, J. and Dummer, R. (2019). Binimetinib in heavily pretreated patients with NRAS‐mutant melanoma with brain metastases. British Journal of Dermatology, 182 (2), 488-490. doi: 10.1111/bjd.18449

Binimetinib in heavily pretreated patients with NRAS‐mutant melanoma with brain metastases

2019

Journal Article

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

Johnson, Douglas B., McDonnell, Wyatt J., Gonzalez-Ericsson, Paula I., Al-Rohil, Rami N., Mobley, Bret C., Salem, Joe-Elie, Wang, Daniel Y., Sanchez, Violeta, Wang, Yu, Chastain, Cody A., Barker, Kristi, Liang, Yan, Warren, Sarah, Beechem, Joseph M., Menzies, Alexander M., Tio, Martin, Long, Georgina V., Cohen, Justine V., Guidon, Amanda C., O'Hare, Meabh, Chandra, Sunandana, Chowdhary, Akansha, Lebrun-Vignes, Benedicte, Goldinger, Simone M., Rushing, Elisabeth J., Buchbinder, Elizabeth I., Mallal, Simon A., Shi, Chanjuan, Xu, Yaomin ... Balko, Justin M. (2019). A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nature Medicine, 25 (8), 1243-1250. doi: 10.1038/s41591-019-0523-2

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

2019

Journal Article

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

Jansen, Y. J. L., Rozeman, E. A., Mason, R., Goldinger, S. M., Foppen, M. H. Geukes, Hoejberg, L., Schmidt, H., van Thienen, J., Haanen, J. B. A. G., Tiainen, L., Svane, I. M., Makela, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A. M., Long, G., Atkinson, V., Blank, C. U. and Neyns, B. (2019). Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Annals of Oncology, 30 (7), 1154-1161. doi: 10.1093/annonc/mdz110

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

2019

Journal Article

The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma

Graf, N. P., Koelblinger, P., Galliker, N., Conrad, S., Barysch, M., Mangana, J., Dummer, R., Cheng, P. F. and Goldinger, S. M. (2019). The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. Journal of the European Academy of Dermatology and Venereology, 33 (4), 686-692. doi: 10.1111/jdv.15363

The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma

Supervision

Availability

Associate Professor Simone M Goldinger is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Media

Enquiries

For media enquiries about Associate Professor Simone M Goldinger's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au